Current Clinical Trials

For enquiries, please email clinical.trials@nccs.com.sg

Phase 1

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	CRC, Ovarian & Endometrial	IV	D3-002 A Phase 1A/B study to evaluate the safety and tolerability of ET-1922159 in advanced solid tumours	Dr Matthew Ng	NCT02521844	Open
2	Epithelial sarcoma, NPC, Gastric, Prostate Ovarian & DLBCL	IV	CMAK683X2101 A Phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies	Dr Daniel Tan	NCT02900651	On hold
3	NSCLC, Melanoma, all solid tumors except CRC	IV	CTNO155X2101 An Open-label, multi-center, Phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors	Dr Daniel Tan	NCT03114319	Open
4	PDAC	Advanced	CTMT212XSG01T Phase Ib study evaluating safety and tolerability of combination trametinib and ruxolitinib in patients with advanced RAS mutant colorectal cancer and pancreatic adenocarcinoma	Dr David Tai	NCT04303403	Open
5	Lung	LOCALLY ADVANCED/ METASTATIC - First Line	CPDR001C2101 Phase 1b, multicenter, open label, 3 arm, dose de-escalation study of PDR001 in combination with platinum-doublet chemotherapy in 1st line, PD-L1 unselected, NSCLC patients	Dr Daniel Tan	NCT03064854	Open
6	All Solid Tumour	documented RET infusion	LOXO-RET-17001 A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity	Dr Daniel Tan	NCT03157128	Open
7	NSCLC, Pancreas and all solid tumors	IV	MCLA-128-CL01 A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors	Dr Justina Lam	NCT02912949	Open
8	All Solid Tumour with documented NTRK fusions	must had prior TRK inhibitor	LOXO-EXT-17005 A Phase 1/2 study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK fusion cancers	Dr Daniel Tan	NCT03215511	Open
9	NSCLC	with documented EGFR Exon 20 insertion mutation	CLN-081-001 A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations	Dr Daniel Tan	NCT04036682	On hold
10	All Solid Tumour	documented RET infusion	LIBRETTO-201 A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation	Dr Daniel Tan	NCT03906331	Open
11	All Solid Tumour	Advanced recurrent	THOR-707-101 An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in a Combination Therapy in Adult Subjects with Advanced or Metastatic Solid Tumors	Dr Tira Tan	NCT04009681	Open
12	All Solid Tumour	Advanced recurrent	TAPISTRY Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial	Dr Tira Tan	NCT04589845	Open
13	NSCLC, CRC	Advanced recurrent	CJDQ443A12101 A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in advanced solid tumor patients harboring the KRAS G12C mutation	Dr Daniel Tan	NCT04699188	Open
14	NSCLC	Advanced recurrent	DESTINY-Lung03 A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03)	Dr Stephanie Saw	NCT04686305	Open
15	NSCLC	Advanced recurrent	Bayer 21607 An open label, first-in-human study of BAY 2927088 in participants with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation	Dr Daniel Tan	NCT05099172	Open
16	NSCLC	Advanced recurrent	BLU-945-1101 A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer	Dr Daniel Tan	NCT04862780	Open
17	Cholangio and all soild tumors	with FGFR2 mutation	RLY-4008-101 A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors Cancers	Dr David Tai	NCT04526106	Open
18	NSCLC HNSCC Urothelial	Advanced recurrent	BAYER 21343 An open-label, Phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in combination with pembrolizumab in participants with advanced solid tumors	Dr Daniel Tan	NCT04999202	On hold
19	All Solid Tumour	Advanced recurrent	ADG116-1003 A Phase 1, Open-Label, Dose Escalation and Expansion Study of ADG116, ADG116 Combined with ADG106 (Anti-CD137 Antibody), ADG116 Combined with Toripalimab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors	Dr Matthew Ng	NCT04501276	Open
20	Breast and Gastric	with HER2+	GO40311 A PHASE Ia/b, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF BTRC4017A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT AND IN COMBINATION WITH TRASTUZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS	Dr Tira Tan	NCT03448042	Open
21	All solid tumours	Advanced recurrent	ADG126-1001 A First-in-Human (FIH), Open-Label, Phase I Dose Escalation and Expansion Study of ADG126, ADG126 in Combination with Toripalimab, and ADG126 in Combination with ADG106 in Patients with Advanced/ Metastatic Solid Tumors	Dr Justina Lam	NCT04645069	Open
22	SCLC	Advanced recurrent	AMGEN20200439 A Phase 1b Study Evaluating the Safety and Efficacy of AMG 757 in Combination with AMG 404 in Subjects with Small Cell Lung Cancer (SCLC)	Dr Daniel Tan	NCT04885998	Open
23	NPC	Recurrent / Metastatic	VT3996-301 An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma	Dr Darren Lim	NCT05166577	Open
24	Sarcoma (Lipo-sarcoma except ddLPS, undifferentiated pleo-mophic sarcoma, myxofibro-sarcoma, synovial sarcoma and leimyo sarcoma	TP53 Wild type	BI 1403-0002 A phase 1a/1b, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) and BI 754111 and the combination of BI 907828 with BI 754091(ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors.	Dr Darren Lim	NCT03964233	Open
25	HCC	Advanced recurrent	SCG 101-UR-103 A Phase I/ IIa, single arm, multicenter study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma	Dr Toh Han Chong	NCT05417932	On hold
26	HCC (positive GPC3 expression )	Recurrent/ Metastatic	TCD17240 A Phase 1/2 open-label, first-in-human, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR444200-based regimen in participants with advanced solid tumors	Dr Darren Lim	NCT05450562	Open
27	All solid tumours	KRAS G12Cmut	CJDQ443E12101 A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in advanced solid tumor patients harboring the KRAS G12C mutation	Dr Stephanie Saw	NCT05358249	Open
28	All solid tumours	Prior IO responders	BAYER 21820 First-in-human dose-escalation and expansion study of the anti-CCR8 antibody BAY 3375968 in combination with pembrolizumab to evaluate the safety, tolerability, and pharmacokinetics in participants with selected advanced solid tumors	Dr Tira Tan	NCT05537740	Open

Current clinical trials by body parts

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	Breast	Metastatic	BEXMET Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells from a Mesenchymal-Like to an Epithelial-Like Phenotype	Dr Elaine Lim	NCT04664829	Open
2	Breast	PIK3 CA-Mutant HR+, HER2 - LABC/MBC	WO41554 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GDC 0077 Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant In Patients with Locally Advanced or Metastatic Pik3ca-Mutant Hormone Receptor-Positive, Her2 Negative Breast Cancer	Dr Yap Yoon Sim	NCT04191499	Open
3	Breast	TNBC	WO39391-IMPASSION 030 A Phase III, Multicenter, Randomized, Open-label Study Comparing ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) In Combination With Standard Adjuvant ANTHRACYCLINE/TAXANE-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable TRIPLE-NEGATIVE Breast Cancer	Dr Rebecca Dent	NCT03498716	On hold
4	Breast	HER2+ Adj	WO42633-Astefania: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Atezolizumab or Placebo in Combination with Trastuzumab Emtansine as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer At Risk of Recurrence Who have Residual Tumor Present Pathologically in the Breast and/or Axillary Lymph Nodes Following Preoperative Therapy	Dr Yap Yoon Sim	NCT04873362	Open
5	Breast	HER2 +	DESTINY-Breast05: A Phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy	Dr Tira Tan	NCT04622319	On hold
6	Breast	Mets TNBC	TROPION Breast02 A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer	Dr Rebecca Dent	NCT05374512	Open
7	Colorectal	Neoadjuvant	OTSP-WoOCRC / MK-3475-886 Window of Opportunity Study with Neoadjuvant Pembrolizumab in MSS & MSI Colorectal Cancer	Dr Iain Tan	NCT03984578	Open
8	Colorectal	Advance 2nd line	Mirati 849-010/KRYSTAL-10 A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy	Dr Dawn Chong	NCT04793958	Open
9	Colorectal	Metastatic 2nd line onwards	CA224-123 Phase 3, Randomized, Open-label (Sponsor Blinded) Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer	Dr Iain Tan	NCT05328908	Open
10	Esophageal	Unresectable Locally Advanced, Unresectable Recurrent, Metastatic, 2nd line	BP42772 A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS WITH ADVANCED OR METASTIC SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS	Dr Lee Suat Ying	NCT04785820	Open
11	Gastric GEJ	Advanced 2nd line	DS8201-A-U306 A Phase 3, multicenter, 2-arm randomized, open-label study of trastuzumab deruxtecan in subjects with HER2-positive advanced gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen	Dr Matthew Ng	NCT04704934	Open
12	Gastric GEJ	Advanced 2nd and 3rd line	ASPEN-06 A Phase 2/3 Study of ALX148 In Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma	Dr Matthew Ng	NCT05002127	Open
13	Gastric GEJ	Advance 1st line	FORTITIUDE-101 A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression	Dr Matthew Ng	NCT05052801	Open
14	GEA	Advance 1st line	ZWI-ZW25-301 A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)	Dr Matthew Ng	NCT05152147	Open
15	Liver	Adv 1st line	JS001-027-III-HCC A prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)	Dr Joycelyn Lee	NCT04523493	Open
16	Liver cancer or Colorectal cancer with liver metastases	Adjuvant	CA209-7R9 An open label, single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) vaccine and anti-PD1 (Nivolumab) as adjuvant treatment in resected hepatocellular carcinoma (HCC) (Group A) and liver metastases from colorectal cancer (CRLM) (Group B)	Dr Koo Si Lin	NCT04912765	Open
17	Liver	Locally advanced	AHCC09 A Multinational, Double-blind, Placebo-Controlled, Parallel Randomized Arms, Phase II trial to Compare the Safety and Efficacy of Selective Internal Radiation Therapy (Y-90 resin microspheres) followed by Atezolizumab plus Bevacizumab versus Selective Internal Radiation Therapy (SIRT-Y90) followed by placebo in patients with locally advanced Hepatocellular Carcinoma	Dr Toh Han Chong	NCT05377034	Open
18	Lung	LOCALLY ADVANCED/ METASTATIC - First Line	BO29554 A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)	Dr Daniel Tan	NCT03178552	Open
19	Lung	Mets NSCLC	KRYSTAL-12 A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation	Dr Ang Mei Kim	NCT04685135	Open
20	Lung	Adjuvant NSCLC	ADAURA2 A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection	Dr Stephanie Saw	NCT05120349	Open
21	Lung	Mets SCLC	20200491 A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 757 in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment	Dr Tan Wan Ling	NCT05060016	Open
22	Lung	Mets NSCLC	STCC-02 / ADIVO Lung / CA209-63C A phase 1b/2 study to evaluate the combination of nivolumab (anti PD1 monoclonal Ab) with ADG106 (4-1-BB agonist monoclonal Ab) in metastatic NSCLC after progression with antiPD1 therapy and platinum-based chemotherapy	Dr Daniel Tan	NCT05236608	Open
23	Lung	Mets NSCLC	HERTHENA–Lung02 A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy	Dr Darren Lim	NCT05338970	Open
24	Lymphoma	Relapsed/Refractory DLBCL	A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma	Dr Miriam Tao	NCT04628494	Open
25	Lymphoma	Relapsed/Refractory EBV+ Lymphomas	VT3996-202 An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Subjects with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)	Dr Nagavalli Somsundaram	NCT05011058	Open
26	Lymphoma	Relapsed/Refractory CLL/SLL	LOXO-BTK-20022 Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322)	Dr Eileen Poon	NCT04965493	Open
27	Head and Neck	ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA First Line	ASPEN03 - AT148003 A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA	Dr Ang Mei Kim	NCT04675294	Open
28	Head and Neck	ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA First Line	ASPEN04 - AT148004 A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB AND CHEMOTHERAPY IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA	Dr Ang Mei Kim	NCT04675333	Open
29	Ovarian	Neoadjuvant	MK4830-002 A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer	Dr Chay Wen Yee	NCT05446870	Open
30	Pancreatic	Metastatic 1st line	CNIS793B12301 A Randomized, Double-blind, Phase III Study, Comparing NIS793 in Combination With Gemcitabine and Nab-paclitaxel Versus (vs.) Placebo Combined With Gemcitabine and Nab-paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2	Dr Joycelyn Lee	NCT04935359	Open
31	Prostate	Metastatic	Bayer 20510: A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH	Dr Ng Quan Sing	NCT04597125	Open
32	Prostate	Metastatic	CAAA617C12301 - PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)	Dr Ravindran Kanesvaran	NCT04720157	Open
33	Renal	Locally advanced / metastatic - 1st line	D5086C00001 (SAMETA): A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Savolitinib plus Durvalumab versus Durvalumab in Participants with MET-Driven, Unresectable and Locally Advanced, or Metastatic Papillary Renal Cell Carcinoma (PRCC)	Dr Ravindran Kanesvaran	NCT05043090	Open
34	Renal	Localised/ Adjuvant	MK6482-022 A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy	Dr Ravindran Kanesvaran	NCT05239728	Open

General

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	SOLID TUMORS	LOCALLY ADVANCED / METASTATIC - ANY LINE	CLDK378A2X01B An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored certinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib	Dr Daniel Tan	NCT02584933	Open
2	SOLID TUMORS	LOCALLY ADVANCED / METASTATIC - ANY LINE	LOXO-TRK-15002 (NAVIGATE) A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors	Dr Daniel Tan	NCT02576431	Open
3	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line Onwards	APL10101 Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Dr Gillianne Lai	NCT03175224	Open
4	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line Onwards	TPX-0005-01 A Phase 1/2, Open-Label, Multi-Center, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 rearrangements (TRIDENT-1)	Dr Darren Lim	NCT03093116	Open
5	SOLID TUMORS (currently only HCC and gastric cohorts are opened)	Advanced curatively unresectable solid tumors failing standard therapy. HCC: must have failed at least 1 line of standard therapy Gastric cancer: must have failed at least 2 line of standard therapy (inclusive of adjuvant treatment) Other solid tumours: must have failed at least 1 line of standard therapy	NCCS-2018-Phase2-PRL3 An open label Phase II study of the efficacy and tolerability of PRL3-ZUMAB and predictive biomarkers in advanced solid tumours	Dr Matthew Ng	NCT04118114	Open
6	SOLID TUMORS	Any solid tumors with peritoneal mets	Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases	Dr Claramae Chia	NCT04956068	Open
7	SOLID TUMORS	ADVANCED/ METASTATIC - 2nd Line	STCC-01 A phase II multi-centre study evaluating the efficacy of dacomitinib for patients with epidermal growth factor receptor (EGFR)-driven advanced solid tumours with low EGFR-AS1 lncRNA expression or other novel emerging biomarkers	Dr Daniel Tan	NCT04946968	Open

Current Clinical Trials

For enquiries, please email clinical.trials@nccs.com.sg

Phase 1

Current clinical trials by body parts

General

Sign up today!